Abstract-The understanding of the contribution of microglial cells to the onset and/or progression chronic neurodegenerative diseases is key to identify disease-modifying therapies, given the strong neuroimmune component of these disorders. In this review, we dissect the different pathways by which microglia can affect, directly or indirectly, neuronal function and dysfunction associated with diseases like Alzheimer's. We here present the rationale for proposing a model to explain the contribution of microglia to the pathophysiology of Alzheimer's disease, defining microglial cells as necessary transducers of pathology and ideal targets for intervention. Ó 2018
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In contrast, TNFa has also been shown to have protective 230 effects against Ab-induced neurodegeneration of rat corti-231 cal neurons (Barger et al., 1995 ing Ab levels or plaque load (Dagher et al., 2015;  434 Spangenberg et al., 2016) . These studies provide strong 435 and independent support to the hypothesis that the patho- (Eikelenboom and Stam, 1982; McGeer et al., 1987; 446 Griffin et al., 1989; Tooyama et al., 1990; Frautschy 447 et al., 1998 (Stevens et al., 2007; Schafer et al., 2012) Through direct interactions, neurons contribute to maintaining microglia in a homeostatic phenotype. A dysregulation of the key pathways depicted in the figure leads to a shift in the microglial phenotype to an activated inflammatory profile. In the context of Alzheimer's disease, microglia can have indirect effects on neurons through the interaction with the main pathological hallmarks (Ab and Tau). On one hand, Ab can have indirect effects on neurons (right; black dotted line), causing abnormal synaptic function, initiating or pre-conditioning synaptic pathology. On the other hand, the accumulation of Ab causes a progressive shift in microglia (left; gray dotted line), inducing a disease-associated phenotype that accelerates the progression of the pathology (direct effect, solid black line). Additionally, microglia is capable of promoting the spread of misfolded Tau (indirect effect, dotted black line), propagating the pathology in AD (direct effect). In this model, microglia would lead the executive phase of synaptic dysfunction and neurodegeneration, evidenced by recent data suggesting an uncoupling of Ab from the beneficial effects observed after targeting microglia. Therefore, targeting the different steps of the sequence summarized in the left side of the figure (microglial route) provides a tantalizing therapeutic opportunity, applicable to advanced stages of AD.
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